Study participants (n = 146; 101 males, 45 females) were enrolled in a 16 - week randomized clinical trial comparing naltrexone
with placebo treatment.
In this new study and for the first time, scientists used functional magnetic resonance imaging (fMRI) combined with a standard clinical trial design to derive an unbiased brain - based neurological marker to predict analgesia associated
with placebo treatment in patients with chronic knee osteoarthritis pain.
The researchers called for more studies to compare the effectiveness of cupping therapy
with placebo treatments.
Not exact matches
In a 564 - person trial, patients whose ovarian cancer recurred (and who had already started
treatment with chemotherapy) given Rubraca, part of a new class of cancer drugs called «PARP» inhibitors, lived, on median, for double the amount of time without their disease getting even worse compared
with those given a
placebo.
In a late - stage study, Aimmune, a biotech immunotherapy allergy
treatment taken via pill, found that of the roughly 500 kids
with peanut allergies between the ages of 4 - 17 who were part of the trial, 67 % of those who received the
treatment were able to tolerate 600 milligrams of peanut protein (about two to four peanuts) after about a year of
treatment, while only 4 % of those who got the
placebo could tolerate that dose of peanut protein.
Patisiran was being evaluated in a late - stage study against a
placebo for the
treatment of patients
with hereditary ATTR (hATTR) amyloidosis
with polyneuropathy.
He contributes to other large - scale clinical trials including SAVE (evaluating whether
treatment of obstructive sleep apnoea
with continuous positive airways pressure can reduce the incidence of serious CV events in patients
with established CVD), and CREDENCE, a randomised, double - blind,
placebo - controlled trial assessing whether canagliflozin can slow the progression of diabetic nephropathy in patients
with type 2 diabetes.
Of them all, giving your baby a probiotic is perhaps the one
treatment that just might help, although a very recent double - blind,
placebo - controlled randomized trial in Australia concluded that «L reuteri DSM 17938 did not benefit a community sample of breastfed infants and formula fed infants
with colic.»
Long - term
treatment with probiotics in primary care patients
with irritable bowel syndrome — a randomised, double - blind,
placebo controlled trial.
In a second study of 18 children
with peanut allergies, the researchers gave the peanut protein
treatment to 12 children and
placebo powder to the other six.
Treatment with zoledronic acid was associated
with an eight percent increase in lumbar spine bone marrow density at 12 weeks relative to the
placebo arm,
with an 11 percent increase at 24 and 48 weeks.
Treatment with zoledronic acid was associated
with a 73 percent and a 65 percent reduction in bone loss relative to
placebo at 12 weeks and 24 weeks respectively, an effect that lasted throughout the 48 weeks of the study.
With two additional years of denusomab
treatment, their bone mineral density increased further and the wrist fracture rate declined to levels significantly lower than the FREEDOM
placebo rate (rate ratio = 0.57, 95 % CI = 0.34 - 0.95; p = 0.03).
Hep C patients being treated for opioid addiction achieved high rates of sustained virologic response after 12 weeks of therapy
with elbasvir - grazoprevir compared to those taking
placebo for 12 weeks before beginning the drug
treatment.
In the four weeks after the first
treatments, people had about 15 percent fewer days of headache compared
with a
placebo or dummy injection.
Researchers here recruited thirty patients
with primary insomnia, who underwent neurofeedback
treatment and
placebo - feedback
treatment over several weeks.
Patients
with cirrhosis were enrolled in 2 cohorts: HCV
treatment - naive or HCV
treatment - experienced; patients within each cohort were also stratified according to HCV genotype 1 subtype (1a or 1b) and randomly assigned to receive weight - based ribavirin (1,000 - 1,200 mg / d) or matching
placebo.
Alternatively, the Institute investigated the benefit and harm of
treatment of ASB detected by screening compared
with non-
treatment or
placebo.
With so much on the line, athletes are willing to try new
treatments that may be groundbreaking cures or just elaborate
placebos.
«Our results show that the number of responders was three times higher when correct information was given than when patients thought they were treated
with an ineffective active
placebo, even though the pharmacological
treatment was identical,» says author Vanda Faria.
The study was not powered to demonstrate a
treatment effect on kidney function, but there was no evidence of a benefit associated
with bosutinib compared
with placebo over the 2 - year
treatment period.
In a related Editor's Note, Deborah Grady, M.D., M.P.H., a deputy editor of JAMA Internal Medicine, writes: «It is possible that
treatment beyond one year would result in better outcomes, but these data provide no support for use of higher - dose cholecalciferol replacement therapy or indeed any dose of cholecalciferol compared
with placebo.»
TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination
with either
placebo or trebananib in previously treated patients
with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line
treatment adding it to carboplatin / paclitaxel.
The overall risk of nausea and vomiting within 24 hours was about 60 percent lower
with gabapentin, compared to inactive
placebo (or other
treatments).
After nine hours, iron in the blood stream had decreased in the
placebo group, whereas this decrease could be prevented by
treatment with lexaptepid.
While the
treatment did have some favorable effects, in the main measure of outcome — measured
with a cognitive test called the Alzheimer's Disease Assessment Scale - cognitive subscale — the researchers did not observe any statistically significant benefit compared
with placebo.
The patients were randomized to
treatment and control arms at a 2:1 ratio (
with 345 treated and 172 receiving
placebo).
Furthermore, the report accuses the British Homeopathic Association (BHA), which had submitted evidence to the panel, of cherry - picking, and even, in one case actively misrepresenting, research into the
treatment (a famous study that concluded its findings were «compatible
with the notion that the clinical effects of homeopathy are
placebo effects» was cited by the BHA as evidence of the
treatment's efficacy.)
Psoriasis patients were randomly divided into two groups,
with 21 patients in the
placebo group and 22 patients receiving the
treatment.
At the end of
treatment, the women who received the drug reported a 21 - point reduction on a standard scale of depression symptoms, compared
with about 9 points for the women on a
placebo.
For individuals
with mild - to - moderate depression, they found that
treatment with an antidepressant was almost no different from
placebo.
However, if SSRIs had indeed acted merely by means of a
placebo effect, these drugs should not outperform actual
placebo in clinical trials where patients have been treated
with an SSRI or
with ineffective
placebo pills, and where neither the physician nor the patient knows which
treatment the patient has been given until the study is over.
Patients taking part in the study will receive either Genistein Aglycone or
placebo (an inactive substance that looks like the
treatment)
with food, over a period of 12 months.
Six weeks of
treatment by the highest dose of dronabinol (10 milligrams) was associated
with a lower frequency of apneas or hypopneas (overly shallow breathing) during sleep, decreased subjective sleepiness and greater overall
treatment satisfaction compared to the
placebo group.
Importantly, compared to
placebo,
treatment with FCM was also associated
with a significant 61 % reduction in the risk of hospitalisation due to worsening heart failure (hazard ratio [HR] 0.39; p = 0.009).
Contrary to the proclamations of many scientists, unreliable medical study results do not disappear
with large, randomized controlled trials, in which subjects are randomly assigned to a
treatment or
placebo group.
Preliminary data show that all executive function domains, except managing affective interference, showed a significant reduction in severity of symptoms during active LDX
treatment versus
treatment with placebo.
The study of 826 women
with previously unexplained recurrent miscarriage showed that those who received progesterone
treatment in early pregnancy were no less likely to miscarry than those who received a
placebo.
According to the trial's crossover design, patients
with refractory chronic cough of at least eight weeks» duration were randomly assigned initially to either AF - 219 or
placebo treatment twice daily for two weeks, followed by a washout period, and further followed by crossover to the alternative
treatment arm (AF - 219 or
placebo) for an additional two weeks.
In a review article published in 2010, physician Max H. Pittler of the German Cochrane Center at the University of Freiburg and physician Edzard Ernst of the Peninsula Medical School in Exeter, England, analyzed 12 well - designed studies comparing kava
with a
placebo for the
treatment of anxiety.
Afferent Pharmaceuticals today announced publication of results from a Phase 2 clinical trial demonstrating that the company's novel drug candidate, AF - 219, reduced daytime cough frequency by 75 % compared to
placebo in patients
with treatment - refractory chronic cough.
But by 2004, after researchers had completed two major parts of the Women's Health Initiative — which together formed a massive study of 27,347 women that compared
treatment with a
placebo in a scientifically rigorous way — doctors realized hormone therapy does more harm than good in most women over the long term.
Among cigarette smokers not willing or able to quit smoking in the next month but willing to reduce
with the goal of quitting in the next 3 months, use of the nicotine addiction medication varenicline for 24 weeks compared
with placebo produced greater reductions in smoking prior to quitting and increased smoking cessation rates at the end of
treatment and at 1 year, according to a study in the February 17 issue of JAMA.
«Cold water in the left ear significantly increased patients» insight and awareness of their schizophrenia, which we measured 30 minutes after the test, compared
with the sham or
placebo treatment using room temperature water,» says Dr. Gerretsen.
Changhai Ding, M.D., Ph.D., of the University of Tasmania, Hobart, Tasmania, Australia, and colleagues randomly assigned 413 patients
with symptomatic knee osteoarthritis and low 25 - hydroxyvitamin D to receive monthly
treatment with oral vitamin D3 (50,000 IU; n = 209) or an identical
placebo (n = 204) for 2 years.
The researchers found that the addition of vitamin D3 to ciclesonide did not significantly reduce the rate of first
treatment failure (a composite outcome of decline in lung function and increases in use of beta - agonists, systemic steroids, and health care utilization) compared
with placebo; 28 percent and 29 percent of participants in each group, respectively, experienced at least 1
treatment failure during 28 weeks.
«It's difficult for experimental drugs to prove their superiority to
placebo treatment and predicting
placebo responders may help to deal
with this challenge,» says Luana Colloca at the National Institutes of Health in Bethesda, Maryland.
Mario Castro, M.D., M.P.H., of the Washington University School of Medicine, St. Louis, and colleagues randomly assigned adults
with asthma and low vitamin D levels to vitamin D3 (100,000 IU once, then 4,000 IU / daily for 28 weeks; n = 201) or
placebo (n = 207), which was added to
treatment with the inhaled corticosteroid ciclesonide.
What the NINDS study showed, Genentech spokesperson Krysta Pellegrino says, is that «patients were at least 30 percent more likely to have a decrease in stroke - related disability three months after
treatment compared
with placebo.»
For the «
Treatment of Severe Childhood Aggression (TOSCA) Study,» 168 children (ages 6 - 12) who had been diagnosed with ADHD and disruptive behavior disorder (DBD) and displayed severe physical aggression were randomly assigned to two groups: parent training plus stimulant plus placebo (Basic treatment) or parent training plus stimulant plus the antipsychotic drug risperidone (Augmented tr
Treatment of Severe Childhood Aggression (TOSCA) Study,» 168 children (ages 6 - 12) who had been diagnosed
with ADHD and disruptive behavior disorder (DBD) and displayed severe physical aggression were randomly assigned to two groups: parent training plus stimulant plus
placebo (Basic
treatment) or parent training plus stimulant plus the antipsychotic drug risperidone (Augmented tr
treatment) or parent training plus stimulant plus the antipsychotic drug risperidone (Augmented
treatmenttreatment).